Published in Neurology on September 13, 2007
Genomewide association study for susceptibility genes contributing to familial Parkinson disease. Hum Genet (2008) 5.04
Genetic animal models of Parkinson's disease. Neuron (2010) 3.86
Genetic etiology of Parkinson disease associated with mutations in the SNCA, PARK2, PINK1, PARK7, and LRRK2 genes: a mutation update. Hum Mutat (2010) 2.29
Advances in the genetics of Parkinson disease. Nat Rev Neurol (2013) 2.21
Genome-wide association study confirms extant PD risk loci among the Dutch. Eur J Hum Genet (2011) 2.12
Post-transcriptional regulation of alpha-synuclein expression by mir-7 and mir-153. J Biol Chem (2010) 1.94
What causes cell death in Parkinson's disease? Ann Neurol (2008) 1.66
SNCA variant associated with Parkinson disease and plasma alpha-synuclein level. Arch Neurol (2010) 1.54
Head injury, α-synuclein genetic variability and Parkinson's disease. Eur J Neurol (2014) 1.48
Independent and joint effects of the MAPT and SNCA genes in Parkinson disease. Ann Neurol (2011) 1.40
Genetic regulation of alpha-synuclein mRNA expression in various human brain tissues. PLoS One (2009) 1.34
α-Synuclein genetic variants predict faster motor symptom progression in idiopathic Parkinson disease. PLoS One (2012) 1.33
Vitamin D receptor gene as a candidate gene for Parkinson disease. Ann Hum Genet (2011) 1.22
Expansion of the Parkinson disease-associated SNCA-Rep1 allele upregulates human alpha-synuclein in transgenic mouse brain. Hum Mol Genet (2009) 1.21
In vivo silencing of alpha-synuclein using naked siRNA. Mol Neurodegener (2008) 1.18
Gene-environment interactions: key to unraveling the mystery of Parkinson's disease. Prog Neurobiol (2011) 1.14
Toxin-induced and genetic animal models of Parkinson's disease. Parkinsons Dis (2010) 1.04
The effect of SNCA 3' region on the levels of SNCA-112 splicing variant. Neurogenetics (2010) 1.03
Genetic variability at the PARK16 locus. Eur J Hum Genet (2010) 1.01
Reply to: SNCA variants are associated with increased risk of multiple system atrophy. Ann Neurol (2010) 1.00
A single nucleotide polymorphism in the 3'UTR of the SNCA gene encoding alpha-synuclein is a new potential susceptibility locus for Parkinson disease. Neurosci Lett (2009) 0.98
Association of alpha-, beta-, and gamma-Synuclein with diffuse lewy body disease. Arch Neurol (2010) 0.95
Physiological and pathological role of alpha-synuclein in Parkinson's disease through iron mediated oxidative stress; the role of a putative iron-responsive element. Int J Mol Sci (2009) 0.92
α-Synuclein and neuronal cell death. Mol Neurobiol (2012) 0.92
The therapeutic potential of LRRK2 and alpha-synuclein in Parkinson's disease. Antioxid Redox Signal (2009) 0.90
Protective effect of LRRK2 p.R1398H on risk of Parkinson's disease is independent of MAPT and SNCA variants. Neurobiol Aging (2013) 0.89
The Broad Impact of TOM40 on Neurodegenerative Diseases in Aging. J Parkinsons Dis Alzheimers Dis (2014) 0.88
Circadian dysfunction may be a key component of the non-motor symptoms of Parkinson's disease: insights from a transgenic mouse model. Exp Neurol (2013) 0.87
Molecular insights into Parkinson's disease. F1000 Med Rep (2011) 0.87
A cytosine-thymine (CT)-rich haplotype in intron 4 of SNCA confers risk for Lewy body pathology in Alzheimer's disease and affects SNCA expression. Alzheimers Dement (2015) 0.86
Genetic variability in SNCA and Parkinson's disease. Neurogenetics (2011) 0.85
DJ-1 interactions with α-synuclein attenuate aggregation and cellular toxicity in models of Parkinson's disease. Cell Death Dis (2014) 0.85
New brain-specific beta-synuclein isoforms show expression ratio changes in Lewy body diseases. Neurogenetics (2011) 0.84
Variants in the 3'UTR of SNCA do not affect miRNA-433 binding and alpha-synuclein expression. Eur J Hum Genet (2012) 0.84
The genetic contributions of SNCA and LRRK2 genes to Lewy Body pathology in Alzheimer's disease. Hum Mol Genet (2014) 0.83
Variant in the 3' region of SNCA associated with Parkinson's disease and serum α-synuclein levels. J Neurol (2011) 0.82
Tyrosine hydroxylase gene: another piece of the genetic puzzle of Parkinson's disease. CNS Neurol Disord Drug Targets (2012) 0.81
Higher vulnerability and stress sensitivity of neuronal precursor cells carrying an alpha-synuclein gene triplication. PLoS One (2014) 0.80
Up-regulation of SNCA gene expression: implications to synucleinopathies. Neurogenetics (2016) 0.80
The PD-associated alpha-synuclein promoter Rep1 allele 2 shows diminished frequency in restless legs syndrome. Neurogenetics (2014) 0.78
Inclusion of a portion of the native SNCA 3'UTR reduces toxicity of human S129A SNCA on striatal-projecting dopamine neurons in rat substantia nigra. Dev Neurobiol (2012) 0.78
Structural variants in SNCA gene and the implication to synucleinopathies. Curr Opin Genet Dev (2017) 0.75
Analysis of LRRK2, SNCA, and ITGA8 Gene Variants with Sporadic Parkinson's Disease Susceptibility in Chinese Han Population. Parkinsons Dis (2016) 0.75
Variants in SNCA Gene Are Associated with Parkinson's Disease Risk and Cognitive Symptoms in a Brazilian Sample. Front Aging Neurosci (2017) 0.75
Genetic Variants in SNCA and the Risk of Sporadic Parkinson's Disease and Clinical Outcomes: A Review. Parkinsons Dis (2017) 0.75
Interpreting Gene Expression Effects of Disease-Associated Variants: A Lesson from SNCA rs356168. Front Genet (2017) 0.75
The complete genome sequence of the gram-positive bacterium Bacillus subtilis. Nature (1997) 33.47
alpha-Synuclein locus triplication causes Parkinson's disease. Science (2003) 20.20
Association of missense and 5'-splice-site mutations in tau with the inherited dementia FTDP-17. Nature (1998) 15.24
NDT80, a meiosis-specific gene required for exit from pachytene in Saccharomyces cerevisiae. Mol Cell Biol (1995) 3.82
Noninvasive diagnosis of ischemia-induced wall motion abnormalities with the use of high-dose dobutamine stress MRI: comparison with dobutamine stress echocardiography. Circulation (1999) 3.44
A major lung cancer susceptibility locus maps to chromosome 6q23-25. Am J Hum Genet (2004) 3.05
N-WASP deficiency reveals distinct pathways for cell surface projections and microbial actin-based motility. Nat Cell Biol (2001) 2.91
Lewy bodies and parkinsonism in families with parkin mutations. Ann Neurol (2001) 2.50
Noninvasive detection of myocardial ischemia from perfusion reserve based on cardiovascular magnetic resonance. Circulation (2000) 2.49
The DYT1 phenotype and guidelines for diagnostic testing. Neurology (2000) 2.39
VMAT2 knockout mice: heterozygotes display reduced amphetamine-conditioned reward, enhanced amphetamine locomotion, and enhanced MPTP toxicity. Proc Natl Acad Sci U S A (1997) 2.34
alpha-Synuclein shares physical and functional homology with 14-3-3 proteins. J Neurosci (1999) 2.25
A randomized, controlled study to assess the conversion from calcineurin-inhibitors to everolimus after liver transplantation--PROTECT. Am J Transplant (2012) 2.24
A variant of Alzheimer's disease with spastic paraparesis and unusual plaques due to deletion of exon 9 of presenilin 1. Nat Med (1998) 2.20
Haplotypes and gene expression implicate the MAPT region for Parkinson disease: the GenePD Study. Neurology (2008) 2.16
Motor blocks in Parkinson's disease. Neurology (1992) 2.01
LRRK2 mutations in Parkinson disease. Neurology (2005) 2.01
A G protein-coupled receptor for UDP-glucose. J Biol Chem (2000) 1.91
Phenotype in parkinsonian and nonparkinsonian LRRK2 G2019S mutation carriers. Neurology (2011) 1.90
Epidemiologic study of 203 sibling pairs with Parkinson's disease: the GenePD study. Neurology (2002) 1.90
A loss of function mutation of presenilin-2 interferes with amyloid beta-peptide production and notch signaling. J Biol Chem (1999) 1.87
The UV response involving the Ras signaling pathway and AP-1 transcription factors is conserved between yeast and mammals. Cell (1994) 1.85
DJ-1 (PARK7) mutations are less frequent than Parkin (PARK2) mutations in early-onset Parkinson disease. Neurology (2004) 1.83
Distinctive neuropathology revealed by alpha-synuclein antibodies in hereditary parkinsonism and dementia linked to chromosome 4p. Acta Neuropathol (2000) 1.79
Transgenic mice with increased Cu/Zn-superoxide dismutase activity are resistant to N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity. J Neurosci (1992) 1.79
The 'essentials' of essential palatal tremor: a reappraisal of the nosology. Brain (2005) 1.78
Primary focal dystonia: evidence for distinct neuropsychiatric and personality profiles. J Neurol Neurosurg Psychiatry (2009) 1.70
Localization of a gene for myoclonus-dystonia to chromosome 7q21-q31. Ann Neurol (1999) 1.67
Widespread alterations of alpha-synuclein in multiple system atrophy. Am J Pathol (1999) 1.65
Heterozygous carriers of a Parkin or PINK1 mutation share a common functional endophenotype. Neurology (2008) 1.60
Left ventricular remodelling and brain natriuretic peptide after first myocardial infarction. Heart (2001) 1.60
Simple-sugar meals target GLUT2 at enterocyte apical membranes to improve sugar absorption: a study in GLUT2-null mice. J Physiol (2003) 1.56
EFNS/MDS-ES/ENS [corrected] recommendations for the diagnosis of Parkinson's disease. Eur J Neurol (2013) 1.52
Further evidence for a somatic KRAS mutation in a pilocytic astrocytoma. Neuropediatrics (2007) 1.52
Neurosurgical intervention for cervical disk disease in dystonic cerebral palsy. Mov Disord (1998) 1.51
Head injury, α-synuclein genetic variability and Parkinson's disease. Eur J Neurol (2014) 1.48
Lack of nigral pathology in transgenic mice expressing human alpha-synuclein driven by the tyrosine hydroxylase promoter. Neurobiol Dis (2001) 1.48
Long-term fecal excretion and resistance induced in mice infected with Yersinia enterocolitica. Infect Immun (1978) 1.47
Compartmentation of Fyn kinase with glycosylphosphatidylinositol-anchored molecules in oligodendrocytes facilitates kinase activation during myelination. J Biol Chem (1999) 1.45
A chromosome 4p haplotype segregating with Parkinson's disease and postural tremor. Hum Mol Genet (1999) 1.43
Positron emission tomographic analysis of the nigrostriatal dopaminergic system in familial parkinsonism associated with mutations in the parkin gene. Ann Neurol (2001) 1.42
Evidence for linkage of restless legs syndrome to chromosome 9p: are there two distinct loci? Neurology (2007) 1.42
Lower cardiac mortality in smokers following thrombolysis for acute myocardial infarction may be related to more effective fibrinolysis. QJM (1999) 1.41
Cerebrospinal fluid biomarkers of neurodegeneration in patients with juvenile and classic myotonic dystrophy type 1. Eur J Neurol (2013) 1.41
Inequalities and health. Lancet (1994) 1.40
Correlation between triplet repeat expansion and computed tomography measures of caudate nuclei atrophy in Huntington's disease. J Neurol (1999) 1.40
Parkinson's disease in twins: a follow-up study. Neurology (1999) 1.40
Degradable bisphosphonate-alkaline phosphatase-complexed hydroxyapatite implants in vitro. J Bone Miner Res (1997) 1.40
Lrrk2 R1441C parkinsonism is clinically similar to sporadic Parkinson disease. Neurology (2008) 1.39
The link between the Department of Pathology and Laboratory Medicine and medical administration. Managing the quality continuum. Am J Clin Pathol (1995) 1.38
[Treatment of sialorrhea with botulinum toxin: an overview]. Nervenarzt (2005) 1.38
The effect of halothane on the recirculatory pharmacokinetics of physiologic markers. Anesthesiology (1997) 1.38
High mutation rate in dopa-responsive dystonia: detection with comprehensive GCHI screening. Neurology (2005) 1.34
Induction of phosphodiesterase by cyclic adenosine 3':5'-monophosphate in differentiating Dictyostelium discoideum amoebae. J Biol Chem (1975) 1.33
Fate of virus DNA in the abortive infection of human lymphoid cell lines by Epstein-Barr virus. J Gen Virol (1972) 1.33
Evaluation of 50 probands with early-onset Parkinson's disease for Parkin mutations. Neurology (2002) 1.32
Recombinant growth differentiation factor-9 (GDF-9) enhances growth and differentiation of cultured early ovarian follicles. Endocrinology (1999) 1.31
Spinocerebellar ataxia type 2 with parkinsonism in ethnic Chinese. Neurology (2000) 1.31
Chalcone derivatives antagonize interactions between the human oncoprotein MDM2 and p53. Biochemistry (2001) 1.30
Mutation detection rate and spectrum in familial hypercholesterolaemia patients in the UK pilot cascade project. Clin Genet (2010) 1.29
Anatomical localization of leucine-rich repeat kinase 2 in mouse brain. Neuroscience (2006) 1.28
Expanded motor and psychiatric phenotype in autosomal dominant Segawa syndrome due to GTP cyclohydrolase deficiency. J Neurol Neurosurg Psychiatry (2006) 1.27
Adenylate cyclase activity in Dictyostelium discoideum amoebae and its changes during differentiation. FEBS Lett (1976) 1.27
cAMP,-induced changes in cAMP-binding sites on D; discoideum amebae. Cell (1977) 1.26
Transoral decompression, anterior plate fixation, and posterior wire fusion for irreducible atlantoaxial kyphosis in rheumatoid arthritis. Spine (Phila Pa 1976) (2000) 1.26
Genome-wide scan for Parkinson's disease: the GenePD Study. Neurology (2001) 1.25
Summary of the recommendations of the EFNS/MDS-ES review on therapeutic management of Parkinson's disease. Eur J Neurol (2013) 1.24
Tumor necrosis factor-alpha-induced adipose-related protein (TIARP), a cell-surface protein that is highly induced by tumor necrosis factor-alpha and adipose conversion. J Biol Chem (2001) 1.22
Growth phase-dependent regulation and membrane localization of SpaB, a protein involved in biosynthesis of the lantibiotic subtilin. Appl Environ Microbiol (1994) 1.21
Clinical findings of a myoclonus-dystonia family with two distinct mutations. Neurology (2002) 1.20
Change in ST segment elevation 60 minutes after thrombolytic initiation predicts clinical outcome as accurately as later electrocardiographic changes. Heart (1997) 1.20
Differential effects of PINK1 nonsense and missense mutations on mitochondrial function and morphology. Exp Neurol (2009) 1.19
Novel mutation in the TOR1A (DYT1) gene in atypical early onset dystonia and polymorphisms in dystonia and early onset parkinsonism. Neurogenetics (2001) 1.18
Motor reorganization in asymptomatic carriers of a single mutant Parkin allele: a human model for presymptomatic parkinsonism. Brain (2005) 1.18
Variant ataxia-telangiectasia presenting as primary-appearing dystonia in Canadian Mennonites. Neurology (2012) 1.17
Phenotypic features of myoclonus-dystonia in three kindreds. Neurology (2002) 1.17
Mutations in DYT1: extension of the phenotypic and mutational spectrum. Neurology (2004) 1.15
Origin of the mutations in the parkin gene in Europe: exon rearrangements are independent recurrent events, whereas point mutations may result from Founder effects. Am J Hum Genet (2001) 1.13
Measure of tissue resistivity in experimental electrical burns. J Trauma (1985) 1.13
Dopamine transmission in DYT1 dystonia: a biochemical and autoradiographical study. Neurology (2002) 1.12
Myoclonus-dystonia, obsessive-compulsive disorder, and alcohol dependence in SGCE mutation carriers. Neurology (2007) 1.12
cAMP induces a rapid and reversible modification of the chemotactic receptor in Dictyostelium discoideum. J Cell Biol (1985) 1.11
Myoclonus-dystonia: significance of large SGCE deletions. Hum Mutat (2008) 1.10
Mediators of inflammation and acute phase response in the liver. Cell Mol Biol (Noisy-le-grand) (2001) 1.10
New challenges for informed consent through whole genome array testing. J Med Genet (2009) 1.10
Quality assurance for pharmacy-prepared sterile products in hospitals and home infusion facilities. Am J Health Syst Pharm (1996) 1.10
Physical and functional heterogeneity in TYMV RNA: evidence for the existence of an independent messenger coding for coat protein. Nucleic Acids Res (1976) 1.09